+Compare
PBLA
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
2.58M

PBLA Panbela Therapeutics Forecast, Technical & Fundamental Analysis

a company, which engages in the development of disruptive therapeutics for medical purposes

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for PBLA with price predictions
07:00 PM EST Nov 30, 2023

PBLA in upward trend: price may jump up because it broke its lower Bollinger Band on November 09, 2023

PBLA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 40 cases where PBLA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PBLA's RSI Oscillator exited the oversold zone, of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where PBLA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on December 01, 2023. You may want to consider a long position or call options on PBLA as a result. In of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PBLA just turned positive on November 24, 2023. Looking at past instances where PBLA's MACD turned positive, the stock continued to rise in of 33 cases over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where PBLA advanced for three days, in of 155 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBLA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PBLA entered a downward trend on December 01, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.358) is normal, around the industry mean (20.645). P/E Ratio (0.002) is within average values for comparable stocks, (137.274). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.009).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PBLA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PBLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 3%. For the same Industry, the average monthly price growth was 31%, and the average quarterly price growth was 27%. MMIRF experienced the highest price growth at 247%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 173%. For the same stocks of the Industry, the average monthly volume growth was -7% and the average quarterly volume growth was 52%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 58
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: 25 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

PBLA is expected to report earnings to fall 36.62% to -359 cents per share on May 16

Panbela Therapeutics PBLA Stock Earnings Reports
Q1'23
Est.
$-3.60
Q4'22
Missed
by $1.97
Q3'22
Beat
by $0.02
Q2'22
Missed
by $1.25
Q1'22
Missed
by $0.02
The last earnings report on March 23 showed earnings per share of -567 cents, missing the estimate of -371 cents. With 306.32K shares outstanding, the current market capitalization sits at 2.58M.
A.I. Advisor
published General Information

General Information

a company, which engages in the development of disruptive therapeutics for medical purposes

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
712 Vista Boulevard
Phone
+1 952 479-1196
Employees
7
Web
https://www.panbela.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ALLR0.590.04
+6.68%
Allarity Therapeutics
CCNE20.750.41
+2.02%
CNB Financial Corp
HNI39.690.62
+1.59%
HNI Corp
BWA33.950.26
+0.77%
BorgWarner
FORA2.70-0.01
-0.37%
Forian

PBLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBLA has been closely correlated with VSTM. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if PBLA jumps, then VSTM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBLA
1D Price
Change %
PBLA100%
+13.00%
VSTM - PBLA
77%
Closely correlated
+0.29%
APLMW - PBLA
35%
Loosely correlated
+2.56%
VANI - PBLA
26%
Poorly correlated
+0.67%
SPRO - PBLA
24%
Poorly correlated
+2.63%
CLNN - PBLA
24%
Poorly correlated
-1.83%
More

Groups containing PBLA

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBLA
1D Price
Change %
PBLA100%
+13.00%
PBLA
(undefined stocks)
79%
Closely correlated
+6.65%
biopharma
(undefined stocks)
67%
Closely correlated
+8.51%
medical
(undefined stocks)
40%
Loosely correlated
+0.47%
therapeutics
(undefined stocks)
33%
Poorly correlated
+2.84%